SLGL

Sol-Gel Technologies Ltd.
CAPPED RATING

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Sol-Gel Technologies Ltd. (SLGL) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C
Factor Score 2.3 / 5.0
Growth
D-
Factor Score 0.9 / 5.0
Profitability
C
Factor Score 2.3 / 5.0
Momentum
C+
Factor Score 2.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -6.9
EV / EBITDA -7.7
Rev Growth YoY -96.6%
Gross Margin 0.0%
Price Return 3M -33.6%
Price Return 12M 75.0%
Catalyst Signal 0.00
Market Cap $180.5M
TTM Revenue $1.8M
Price / Sales 100.5
ROE -40.9%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C (2.3) D- (0.9) C (2.3) C+ (2.6) C+ (2.6) C (2.2)
2026-11-07 C (2.3) D- (0.8) C (2.3) C+ (2.7) C+ (2.7) C (2.2)
2026-10-31 C (2.2) D- (0.8) C (2.3) C+ (2.7) C+ (2.7) C- (2.1)
2026-10-24 C (2.2) D- (0.8) C (2.3) C (2.2) C+ (2.6) C- (2.0)
2026-10-17 C (2.3) D- (0.8) C (2.3) C (2.3) C+ (2.6) C- (2.1)
Page 1 of 3